Interaction of cannabidiol with other antiseizure medications: A narrative review

@article{Gilmartin2020InteractionOC,
  title={Interaction of cannabidiol with other antiseizure medications: A narrative review},
  author={Christopher G.S. Gilmartin and Zoya Dowd and Alasdair Parker and Pooja Devi Harijan},
  journal={Seizure},
  year={2020},
  volume={86},
  pages={189-196}
}
View on Elsevier
seizure-journal.com
12 Citations
Background Citations
3

12 Citations

Pharmacokinetic Drug–Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients

The purpose of this review is to present data from the last few years on drug–drug interactions among of Aeds, as well as AEDs with other drugs, nutrients and food, and to pay a special attention to the new potential interactions of the applied first-generation AEDS.

Cannabidiol and epilepsy in Brazil: a current review

CBD is a recognized novel treatment for epilepsy and future well-designed studies and public health strategies are needed to offer widespread access to CBD, and to improve the quality of life of people living with epilepsy in Brazil.

Cannabidiol in canine epilepsy.

Safety and efficacy of cannabidiol-cannabidiolic acid rich hemp extract in the treatment of refractory epileptic seizures in dogs

The use of 2 mg/kg every 12 h of a CBD/CBDA-rich hemp extract can have benefits in reducing the incidence of epileptic seizures, when used concurrently with other ASMs.

Cannabis-based magistral formulation is highly effective as an adjuvant treatment in drug-resistant focal epilepsy in adult patients: an open-label prospective cohort study

The CBMF is a highly effective and safety therapy to treat adult patients with DRFE, and the reduction in seizures frequency is maintained over time.

Effects of chronic cannabidiol in a mouse model of naturally occurring neuroinflammation, neurodegeneration, and spontaneous seizures

The effects of chronic CBD administration in a mouse model of CLN1 disease (Cln1-/-) that simultaneously exhibits neuroinflammation, neurodegeneration, and spontaneous seizures are determined, consistent with CBD having immunomodulatory effects.

What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps?

Most scientific data support the therapeutic potential of cannabis in neurological disorders, but there is an urgent need to manage clinical studies to provide stronger evidence and secure medical cannabis use.

Hepatotoxicity due to herbal dietary supplements: Past, present and the future

Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations.

Pharmacologie du cannabidiol : points de vigilance, conséquences et risques chez l’homme

References

SHOWING 1-10 OF 47 REFERENCES

A perspective on cannabinoids for treating epilepsy: Do they really change the landscape?

Effects of cannabidiol on brivaracetam plasma levels

A case series of five patients receiving adjunctive treatment with CBD showed increases in brivaracetam (BRV) levels by 95% to 280%.

Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome

Among children and adults with the Lennox–Gastaut syndrome, the addition of cannabidiol at a dose of 10 mg or 20 mg per kilogram per day to a conventional antiepileptic regimen resulted in greater reductions in the frequency of drop seizures than placebo.

Cannabinoid therapy in epilepsy

Based on clinical trial data, Epidiolex is the first CBD medication approved by a national regulatory agency (US Food and Drug Administration for Dravet and Lennox Gastaut syndrome) and the complete spectrum of use of cannabis-derived products, and the use of CBD for other epilepsy syndromes remains to be determined.

Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions

The present study aimed to address the nature of the interaction between CBD and clobazam to address speculation that the anticonvulsant efficacy of CBD may simply reflect CBD augmenting clobzam exposure.

Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex.

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

This study provides Class I evidence that for children with Dravet syndrome, CBD resulted in more AEs than placebo but was generally well-tolerated.

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial

Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy

Under an expanded access investigational new drug (IND) trial, cannabidiol (CBD) is being studied as a possible adjuvant treatment of refractory epilepsy in children, and it is predicted a drug–drug interaction.

Cannabidiol Interacts Significantly with Everolimus-Report of a Patient with Tuberous Sclerosis Complex.

Although never before reported, CBD and EVE appear to interact, due to the metabolic pathway through CYP 450 3A4, and although no side effects were detected in this patient, it is strongly recommend drug monitoring using the combination of CBD with EVE to prevent harmful overdosing.